Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Myriad Genetics Inc MYGN

Healthcare Biotechnology
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has... see more

Recent & Breaking News (NDAQ:MYGN)

Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

GlobeNewswire January 18, 2024

Levi & Korsinsky, LLP Notifies Shareholders of Myriad Genetics, Inc. (MYGN) an Upcoming Claims Deadline in a Class Action Settlement

Accesswire January 15, 2024

Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO

GlobeNewswire January 9, 2024

Levi & Korsinsky, LLP Notifies Shareholders of Myriad Genetics, Inc. (MYGN) an Upcoming Claims Deadline in a Class Action Settlement

Accesswire January 9, 2024

Levi & Korsinsky, LLP Notifies Shareholders of Myriad Genetics, Inc. (MYGN) an Upcoming Claims Deadline in a Class Action Settlement

Accesswire January 5, 2024

Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance

GlobeNewswire December 21, 2023

Levi & Korsinsky, LLP Notifies Shareholders of Myriad Genetics, Inc. (MYGN) an Upcoming Claims Deadline in a Class Action Settlement

Accesswire December 20, 2023

Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care

GlobeNewswire December 20, 2023

Levi & Korsinsky, LLP Notifies Shareholders of Myriad Genetics, Inc. (MYGN) an Upcoming Claims Deadline in a Class Action Settlement

Accesswire December 14, 2023

Levi & Korsinsky, LLP Notifies Shareholders of Myriad Genetics, Inc. (MYGN) an Upcoming Claims Deadline in a Class Action Settlement

Accesswire December 12, 2023

Levi & Korsinsky, LLP Notifies Shareholders of Myriad Genetics, Inc. (MYGN) an Upcoming Claims Deadline in a Class Action Settlement

Accesswire December 7, 2023

Levi & Korsinsky, LLP Notifies Shareholders of Myriad Genetics, Inc. (MYGN) an Upcoming Claims Deadline in a Class Action Settlement

Accesswire December 5, 2023

Levi & Korsinsky, LLP Notifies Shareholders of Myriad Genetics, Inc. (MYGN) an Upcoming Claims Deadline in a Class Action Settlement

Accesswire November 29, 2023

Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents

GlobeNewswire November 20, 2023

Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers

GlobeNewswire November 16, 2023

Levi & Korsinsky, LLP Notifies Shareholders of Myriad Genetics, Inc. (MYGN) an Upcoming Claims Deadline in a Class Action Settlement

Accesswire November 14, 2023

Myriad Genetics to Participate in Stephens Annual Investment Conference

GlobeNewswire November 9, 2023

Myriad Genetics Announces Pricing of Upsized Offering of Common Stock

GlobeNewswire November 8, 2023

Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock

GlobeNewswire November 8, 2023